FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2986988082> ?p ?o ?g. }

• W2986988082 endingPage "131" @default.
• W2986988082 startingPage "124" @default.
• W2986988082 abstract "El metotrexato (MTX) es el fármaco sistémico más utilizado en el tratamiento de pacientes con artritis idiopática juvenil. Su efectividad viene limitada por el desarrollo de efectos adversos (EA). Estudio observacional descriptivo retrospectivo de la frecuencia y tipo de EA asociados a MTX en pacientes con artritis idiopática juvenil seguidos en un hospital terciario en el periodo 2008-2016. Se estudió a 107 pacientes, 71/107 mujeres (66,3%) con edad al diagnóstico de 6,4 años (RIC 3,1-12,4) durante una mediana de seguimiento de 45,7 meses (RIC 28,8-92,4). El 44,9% (48 pacientes) tenía oligoartritis y el 24,3% (n = 26) poliartritis factor-reumatoide negativo. El 48,6% (52/107) desarrolló EA, siendo los más frecuentes los síntomas gastrointestinales y los trastornos conductuales (35,6% cada uno). La edad mayor de 6 años al inicio del tratamiento aumentaba el riesgo de desarrollar EA, tanto en el estudio univariable (OR=3,5; IC95% 1,5-7,3) como en el multivariable (aumento del riesgo del 12% por año). La dosis, vía de administración o forma clínica no presentaban relación con el desarrollo de EA. Veinte niños precisaron cambio de dosis o vía de administración, resolviéndose el EA en 11 (55%). MTX se suspendió en 37/107 pacientes (34,6%) por EA, principalmente por hipertransaminasemia (n = 14; 37,8%), síntomas gastrointestinales (n = 9; 24,3%) y trastornos conductuales (n = 6; 16,3%). MTX es el tratamiento de elección de niños con artritis idiopática juvenil pero produce EA en prácticamente el 50% de los pacientes. Aunque estos EA no son graves, obligan a interrumpir el tratamiento en el 35%. Methotrexate (MTX) is the drug of choice for juvenile idiopathic arthritis. Its clinical efficacy is limited due to the development of adverse effects (AEs). A retrospective observational study was conducted on the AEs associated with MTX therapy in children diagnosed with juvenile idiopathic arthritis followed-up in a tertiary hospital between 2008 and 2016. The study included a total of 107 patients, of whom 71 (66.3%) were girls (66.3%). The median age at diagnosis was 6.4 years (IQR 3.1-12.4), with a median follow-up of 45.7 months (IQR 28.8-92.4). There were 48 patients (44.9%) with oligoarthritis, and 26 children (24.3%) with rheumatoid-factor negative polyarthritis. Of these, 52/107 (48.6%) developed AEs, with the most frequent being gastrointestinal symptoms (35.6%) and behavioural problems (35.6%). An age older than 6 years at the beginning of therapy increased the risk of developing AEs, both in the univariate (OR=3.5; 95% CI: 1.5-7.3) and multivariate (12% increase per year) analyses. The doses used, administration route, or International League of Associations for Rheumatology (ILAR) classification, were not associated with the development of AEs. Twenty children required a dosage or route of administration modification, which resolved the AE in 11 (55%) cases. MTX was interrupted due to the development of AEs in 37/107 patients (34.6%), mainly due to increased plasma transaminases (n = 14, 37.8%), gastrointestinal symptoms (n = 9, 24.3%) and behavioural problems (n = 6, 16.3%). MTX is the therapy of choice for patients with juvenile idiopathic arthritis, but 50% of the children develop some form of AE. Although the AEs are not severe, they lead to interruption of therapy in 35% of the children." @default.
• W2986988082 created "2019-11-22" @default.
• W2986988082 creator A5011874198 @default.
• W2986988082 creator A5063680146 @default.
• W2986988082 creator A5064492348 @default.
• W2986988082 creator A5077088837 @default.
• W2986988082 creator A5078503652 @default.
• W2986988082 creator A5087693791 @default.
• W2986988082 date "2020-03-01" @default.
• W2986988082 modified "2023-10-02" @default.
• W2986988082 title "Metotrexato en artritis idiopática juvenil: efectos adversos y factores asociados" @default.
• W2986988082 cites W1774306427 @default.
• W2986988082 cites W1980385693 @default.
• W2986988082 cites W1988904506 @default.
• W2986988082 cites W1998355410 @default.
• W2986988082 cites W2001675854 @default.
• W2986988082 cites W2043306063 @default.
• W2986988082 cites W2072225317 @default.
• W2986988082 cites W2085115651 @default.
• W2986988082 cites W2114155762 @default.
• W2986988082 cites W2114323429 @default.
• W2986988082 cites W2122649701 @default.
• W2986988082 cites W2129628367 @default.
• W2986988082 cites W2158558816 @default.
• W2986988082 cites W2162065782 @default.
• W2986988082 cites W2221264044 @default.
• W2986988082 cites W2264184490 @default.
• W2986988082 cites W2342174771 @default.
• W2986988082 cites W2410233572 @default.
• W2986988082 cites W2413239156 @default.
• W2986988082 cites W2417574414 @default.
• W2986988082 cites W2434439854 @default.
• W2986988082 cites W2500288554 @default.
• W2986988082 cites W2520817446 @default.
• W2986988082 cites W2522932413 @default.
• W2986988082 cites W2624671969 @default.
• W2986988082 cites W2794672770 @default.
• W2986988082 cites W2800934085 @default.
• W2986988082 cites W2839208166 @default.
• W2986988082 cites W652439711 @default.
• W2986988082 doi "https://doi.org/10.1016/j.anpedi.2019.05.010" @default.
• W2986988082 hasPublicationYear "2020" @default.
• W2986988082 type Work @default.
• W2986988082 sameAs 2986988082 @default.
• W2986988082 citedByCount "3" @default.
• W2986988082 countsByYear W29869880822020 @default.
• W2986988082 countsByYear W29869880822021 @default.
• W2986988082 crossrefType "journal-article" @default.
• W2986988082 hasAuthorship W2986988082A5011874198 @default.
• W2986988082 hasAuthorship W2986988082A5063680146 @default.
• W2986988082 hasAuthorship W2986988082A5064492348 @default.
• W2986988082 hasAuthorship W2986988082A5077088837 @default.
• W2986988082 hasAuthorship W2986988082A5078503652 @default.
• W2986988082 hasAuthorship W2986988082A5087693791 @default.
• W2986988082 hasBestOaLocation W29869880821 @default.
• W2986988082 hasConcept C29456083 @default.
• W2986988082 hasConcept C71924100 @default.
• W2986988082 hasConceptScore W2986988082C29456083 @default.
• W2986988082 hasConceptScore W2986988082C71924100 @default.
• W2986988082 hasIssue "3" @default.
• W2986988082 hasLocation W29869880821 @default.
• W2986988082 hasOpenAccess W2986988082 @default.
• W2986988082 hasPrimaryLocation W29869880821 @default.
• W2986988082 hasRelatedWork W1506200166 @default.
• W2986988082 hasRelatedWork W1995515455 @default.
• W2986988082 hasRelatedWork W1999344589 @default.
• W2986988082 hasRelatedWork W2039318446 @default.
• W2986988082 hasRelatedWork W2080531066 @default.
• W2986988082 hasRelatedWork W2748952813 @default.
• W2986988082 hasRelatedWork W2789448498 @default.
• W2986988082 hasRelatedWork W2899084033 @default.
• W2986988082 hasRelatedWork W3032375762 @default.
• W2986988082 hasRelatedWork W3108674512 @default.
• W2986988082 hasVolume "92" @default.
• W2986988082 isParatext "false" @default.
• W2986988082 isRetracted "false" @default.
• W2986988082 magId "2986988082" @default.
• W2986988082 workType "article" @default.